Argenx refers to an international biotech company specializing in the development of human antibodies for the treatment of severe autoimmune diseases and cancer. The company's shares recently underwent a significant uptrend, with increased buying from investment firms such as
Candriam S.C.A. Its flagship drug,
Vyvgart, has been making significant strides and has received FDA approval for treating Chronic Inflammatory Demyelinating Polyneuropathy, a rare autoimmune disorder. Argenx also seeks to expand Vyvgart's application, bolstered by its strong Q2 sales. However, the company faces impending competition from
J&J who is gearing up for FDA approval of a similar autoimmune drug. In China, Argenx, in partnership with Zai Lab, received approval for Efgartigimod Alfa Injection for treating Generalized Myasthenia Gravis. Despite these improvements, Argenx's other clinical trials, such as for Efgartigimod in AAV and for Pemphigus, a skin disorder, failed to meet their goals, giving mixed signals in terms of the company's overall growth prospects.
argenx News Analytics from Wed, 01 Nov 2023 07:00:00 GMT to Sun, 08 Sep 2024 13:57:26 GMT -
Rating 6
- Innovation 3
- Information 7
- Rumor -5
